Key Finding
A meta-analysis of 77 RCTs found that acupoint catgut embedding increased pregnancy rates by 65% and significantly improved insulin resistance and overall symptom management in women with PCOS, with a lower adverse event rate than pharmacotherapy.
Could a specialized acupuncture technique help women with polycystic ovary syndrome (PCOS)? A large new study review suggests it might — and the results are encouraging.
PCOS is one of the most common hormonal conditions affecting women of reproductive age. It can cause irregular periods, difficulty getting pregnant, and problems with how the body processes insulin (a hormone that controls blood sugar). While medications exist, many women find them only partially helpful or experience unwanted side effects.
Researchers analyzed 77 carefully controlled clinical trials involving nearly 6,000 women to evaluate a technique called acupoint catgut embedding (ACE). This approach is related to traditional acupuncture but involves placing tiny, absorbable threads under the skin at specific acupuncture points, providing ongoing stimulation over days or weeks rather than just during a single session.
The findings were promising across three key areas. First, women receiving ACE were 24% more likely to experience meaningful overall improvement in their PCOS symptoms compared to those receiving standard treatments alone. Second, and perhaps most importantly for women hoping to conceive, pregnancy rates were 65% higher in the ACE group. Third, insulin resistance — a core problem in PCOS that affects metabolism and fertility — was significantly reduced.
Safety-wise, ACE compared favorably to medication. Side effects were mostly mild, such as minor bruising or brief discomfort at the treatment site, and occurred significantly less often than side effects from drug therapies.
The researchers urge some caution, noting that the quality of individual studies varied and that more standardized research is still needed. Still, these results position ACE as a genuinely interesting complementary option worth discussing with your healthcare team.
If you are curious about acupoint catgut embedding or traditional acupuncture for PCOS, seek out a licensed, qualified acupuncture practitioner with experience in women's health and reproductive conditions.
This systematic review and meta-analysis of 77 RCTs (n = 5,945) evaluated acupoint catgut embedding (ACE) as a treatment for polycystic ovary syndrome (PCOS). ACE demonstrated statistically significant improvements across three primary outcomes: overall clinical effectiveness (RR = 1.24, 95% CI: 1.20–1.28, P < 0.00001), pregnancy rates (RR = 1.65, 95% CI: 1.49–1.82, P < 0.00001), and insulin resistance reduction (MD = −0.38, 95% CI: −0.53 to −0.23, P < 0.00001). Adverse event incidence was significantly lower with ACE than pharmacotherapy (RR = 0.57, 95% CI: 0.36–0.91, P = 0.02), with events largely limited to localized bruising and transient pain. Evidence was assessed using GRADE methodology. Limitations include heterogeneity across diagnostic criteria and study quality variability. Clinically, ACE may serve as an effective, well-tolerated adjunct or alternative for PCOS management, particularly regarding metabolic and reproductive outcomes, pending further standardized RCTs.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 A systematic review of 214 studies found that acupuncture and moxibustion improve endometrial receptivity in IVF-ET patients by enhancing uterine lining thickness, blood flow, and hormone levels through multiple molecular mechanisms including VEGF-mediated angiogenesis and AMPK/mTOR autophagy pathways.
📌 Live birth rate — the outcome most important to patients undergoing acupuncture-assisted IVF — remains one of the least-supported measures in existing clinical trial evidence, highlighting a critical gap between research priorities and patient concerns.
📌 Acupoint application therapy significantly increased high-quality embryo rates to 47% in ovarian endometriosis IVF patients compared to 31% in the placebo group, while normalizing dysregulated follicular steroid hormone levels linked to impaired oocyte yield.